Skip to main content
Clinical Trials/NCT02427412
NCT02427412
Completed
Phase 4

Evaluation of Intraarticular Tranexamic Acid to Reduction of Total Blood Loss Following Knee-Arthroplasty - A Randomized, Prospective, Placebo-Controlled Study

Hvidovre University Hospital1 site in 1 country60 target enrollmentJanuary 2014

Overview

Phase
Phase 4
Intervention
Tranexamic Acid
Conditions
Blood Loss
Sponsor
Hvidovre University Hospital
Enrollment
60
Locations
1
Primary Endpoint
Total estimated blood loss
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

A randomized, prospective, placebo-controlled study which aims to evaluate the effect of combined intraarticular and intravenous Tranexamic acid on total blood loss following unilateral knee replacement versus only intravenous tranexamic acid.

Detailed Description

Intravenous (IV) Tranexamic acid is already well-established and well-documented regarding significant effect on reducing blood loss following knee replacement. A few studies more shown a similar effect of intraarticular (IA) injected Tranexamic acid into the knee joint at the end of surgery for knee replacement. In this study investigators therefore investigate the possible combined effect of added intraarticular tranexamic acid to conventional intravenous Tranexamic acid.

Registry
clinicaltrials.gov
Start Date
January 2014
End Date
May 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Christian Skovgaard Nielsen

MD

Hvidovre University Hospital

Eligibility Criteria

Inclusion Criteria

  • \> 18 years old
  • Unilateral knee replacement
  • Must be able to give oral and written consent

Exclusion Criteria

  • General Anesthetized
  • Allergic to Tranexamic acid
  • In treatment with the following anticoagulants: Adenosine diphosphate receptor inhibitors or vitamin K antagonist within in the last 5 days. Factor Xa inhibitor and thrombin inhibitor.
  • Use of oral anticonceptive.
  • Reduced kidney function (S-creatinine \> 120 micromol/L)
  • Medicine or alcohol abuse
  • Females with menstruation within the last 12 mounts.
  • Any kind of cancer disease
  • Rheumatoid arthritis
  • Have participated in a clinical trial within the last 30 days.

Arms & Interventions

IA Tranexamic acid + IV Tranexamic Acid

3 gram of Tranexamic acid diluted into 30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.

Intervention: Tranexamic Acid

IA Saline Water + IV tranexamic Acid

30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.

Intervention: Saline water

IA Saline Water + IV tranexamic Acid

30 ml Saline Water injected into the knee capsula after ended surgery + 1 g of Tranexamic acid injected intravenous at the start of surgery.

Intervention: Tranexamic Acid

Outcomes

Primary Outcomes

Total estimated blood loss

Time Frame: 24 hours surgery

Secondary Outcomes

  • Thromboembolic complications(90 days postoperative)
  • Total estimated blood loss(2 days after surgery)
  • Blood transfusion(while hospitalized expected 3 days.)

Study Sites (1)

Loading locations...

Similar Trials